Скачать или смотреть Advances in Antibody Discovery for Bispecific Therapeutics | Biology Solutions | Antibody Screening

Rapidly characterize large panels of antibodies for kinetics, affinity, and epitope diversity
Identify species cross-reactivity and target variant cross-reactivity
Obtain high quality data directly from crude hybridoma supernatants
Work with minimal amounts of sample
Build your IP portfolio

This webinar discusses how scientists at Dragonfly Therapeutics have successfully identified lead candidates from the immunization of different species of mice, as well as through yeast display approaches.

Identifying antibodies with high affinity, specificity, and epitope diversity is critical to antibody discovery campaigns. These campaigns can generate hundreds to thousands of potential lead molecules and incomplete characterization at the screening stage can lead to the advancement of antibodies with liabilities or a lack of strong candidates.

Presented by Dan Fallon, Senior Research Associate, Dragonfly Therapeutics